The company serves couples and individuals in Hong Kong and Thailand. As of June 2026, NewGenIvf has expanded beyond core fertility services into digital assets and strategic technology investments, including stakes in AI-powered platforms, signaling a shift toward a broader diversified holding company model.
Cyborg Score Rationale
The company has a market capitalization of approximately $489,512, indicating a micro-cap status. The stock has experienced extreme volatility and the company appears to be navigating capital structure challenges while pursuing diversified investments.
Top Insights
Diversifying beyond core fertility services into AI-powered prediction markets and digital assets as of June 2026
Micro-cap status with market cap under $1 million reflects severe liquidity and capitalization challenges
Serves niche geographic markets (Hong Kong, Thailand) with limited scale relative to global fertility providers
Recent board expansion and capital structure optimization efforts suggest management focus on stabilization
Named Competitors
Virtus Health — Global fertility services provider
Ferring Pharmaceuticals — Fertility treatment pharmaceuticals and services
K25.ai — AI-powered prediction market platform
Recent Developments
(June 2026) Boosts investment stake in K25.ai, an AI-powered prediction market platform
(June 2026) Adds four independent directors to board
(April 2026) Reports strong balance sheet with $32.7 million in total assets and $9.9 million net profit
(January 2026) Strategic investment agreement with K25.ai at $100 million valuation
Open the full interactive NewGenIvf Group Ltd report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.